Diabetology & Metabolic Syndrome
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes with CKD stages 2-4: a target trial emulation
Cohort study of 28,824 peopleGLP-1 receptor agonists
Papers on cardiorenal risk
51 papers16 new in 30 days
Monday, November 9
AHA Scientific Sessions 2026 Abstract
Health Economic Value of Reducing Initiation Delays of Guideline-Directed Therapies for Improving Cardiovascular and Renal Outcomes for Complex Patients with Type 2 Diabetes
Computational studyType 2 diabetes
Saturday, November 7
AHA Scientific Sessions 2026 Abstract
Implementation of Kidney-Protective Therapies and Renal Outcomes in Heart Failure with Diabetic Kidney Disease: A Multicenter Cohort Study
Cohort study of 1,076 peopleDiabetic kidney disease
AHA Scientific Sessions 2026 Abstract
Initial SGLT2 Inhibitor Therapy Followed by GLP-1 Receptor Agonist Addition versus Reverse Sequencing and Cardiorenal Outcomes in Adults with Type 2 Diabetes and CKD Stages 3-4: A Propensity-Matched Real-World Analysis
Cohort study of 37,830 peopleSGLT2 inhibitors
AHA Scientific Sessions 2026 Abstract
Trends and Disparities in Hypertensive Heart and Renal Disease Mortality: A CDC WONDER Analysis, 1999 to 2024
Cross-sectional study of 250,741 peoplePopulations
AHA Scientific Sessions 2026 Abstract
Isolated Diastolic Hypertension in the Presence of Metabolic Dysfunction: A Higher-Risk Phenotype?
Cohort study of 28,901 peopleIsolated diastolic hypertension
Friday, November 6
Annals of Medicine and Surgery
Early finerenone and sodium-glucose cotransporter 2 inhibitor therapy in diabetic kidney disease: a risk-readiness-reassessment framework
CommentarySGLT2 inhibitors
European Journal of Clinical Pharmacology
Clinical pharmacology of antidiabetic drugs: an update
ReviewInterventions
Current Opinion in Nephrology and Hypertension
A practical framework for using GLP-1 RAs, SGLT2i, and MRAs with contemporary immunosuppression in kidney transplant recipients
ReviewSGLT2 inhibitors
Tuesday, November 3
Current Hypertension Reports
Primary Aldosteronism: Evaluation and Management in the Hypertensive Patient
ReviewHypertension
Friday, October 30
Clinical Kidney Journal
Single or multiple nutritional hormone receptor modulators for chronic kidney disease
ReviewChronic kidney disease
Tuesday, October 27
Medicina
Beyond Cardiorenal Risk Factors: The Prognostic Role of Frailty in Acute Heart Failure
Cohort study of 530 peopleAcute heart failure
Monday, October 26
ESC Congress 2026 Abstract
Non-high-density lipoprotein cholesterol and residual cardiorenal risk in statin-treated patients with type 2 diabetes mellitus
Cohort study of 79,008 peopleNon-HDL cholesterol
ESC Congress 2026 Abstract
Stepwise intensification of guideline-directed medical therapy is associated with reduced major adverse kidney events in patients with HFpEF and diabetes
Cohort study of 1,125 peopleGuideline-directed medical therapy
Tuesday, October 20
Journal of Cardiovascular Pharmacology
Finerenone: A Non-Steroidal Mineralocorticoid Receptor Antagonist and Its Emerging Role in Cardiovascular-Kidney-Metabolic Syndrome
ReviewFinerenone
Tuesday, October 13
Clinical Kidney Journal
Combined statin and fenofibrate therapy and cardiorenal outcomes in patients with CKD, dyslipidemia, and ischemic heart disease
Cohort study of 392,969 peopleIschemic heart disease
Monday, October 12
Friday, October 9
Journal of the American Society of Nephrology
A Microsimulation of Eligibility for Cardiorenal Combination Treatment and Potential Deaths Averted
Computational studyInterventions
Frontiers in Pharmacology
SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis
Meta-analysis of randomized trialsSGLT2 inhibitors
Thursday, October 1
Saturday, September 26
Thursday, September 24
Handbook of Experimental Pharmacology
Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors
ReviewSGLT2 inhibitors
Sunday, September 13
Handbook of Experimental Pharmacology
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals
ReviewSGLT2 inhibitors
Wednesday, September 9
Thursday, August 27
Thursday, August 13
Journal of Nephrology
Longitudinal changes in cardiorenal risk scores after SGLT2 inhibitor initiation in patients with CKD with and without type 2 diabetes
Cohort study of 132 peopleSGLT2 inhibitors
Wednesday, August 12
JACC Asia
Lifestyle and Metabolic Health, Low-Grade to Clinically Elevated Albuminuria, and Cardiovascular-Renal Diseases
Cohort study of 82,509 peopleCardiovascular disease
Sunday, June 21
Diabetes Research and Clinical Practice
Exercise as targeted therapy in type 2 diabetes: a phenotype-informed clinical prioritisation framework for adapted physical activity
ReviewExercise
Friday, March 27
Current Opinion in Endocrinology, Diabetes, and Obesity
Metabolic dysfunction and the use of adjunct medications in type 1 diabetes
ReviewMetabolic dysfunction